1. Generics Bulletin
  2. >>Products

Teva’s Francis: I Looked At All The Sexy Stuff And Overlooked Olanzapine

Key Data Read Out For Long-Acting Subcutaneous Olanzapine Set For 2025

 
• By Dean Rudge

After launching the Uzedy long-acting formulation of risperidone in partnership with MedinCell earlier this year, Teva has stressed the “really exciting” product profile of another long-acting antipsychotic from the partnership, olanzapine, while discussing how it will avoid the safety pitfalls of legacy products in the space.

sunset golden crude pipelines in africa
• Source: Shutterstock

Teva’s CEO Richard Francis says that the company’s SOLARIS Phase III clinical study evaluating the company and MedinCell’s proposed first subcutaneous long-acting injectable formulation of olanzapine is “recruiting really well,” while stressing that the asset was – like its long-acting risperidone counterpart – “maybe another one that people don’t look at enough.”

“When I came in,” Francis told attendees to the Morgan Stanley Global Healthcare Conference on 11 September, ten months into his appointment as CEO, “obviously I looked at our TL1A, our anti-PD1-IL2, our

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Value Added Medicines

More from Products

Lupin Touts FDA Approval For Generic Tolvaptan With 180-Day Exclusivity

 
• By Urtė Fultinavičiūtė

After receiving a favorable court ruling last year, Lupin has secured its first-place spot for generic tolvaptan tablets in the US.

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”